亚辉龙收盘下跌1.30%，滚动市盈率37.06倍，总市值91.04亿元

Company Overview - Shenzhen Aihuilong Biotechnology Co., Ltd. specializes in the research, production, and sales of in vitro diagnostic instruments and related reagents, primarily using chemiluminescence immunoassay technology [2] - The company has developed a fully automated immunoassay system, breaking the technological monopoly of foreign giants in the field of acridinium ester direct chemiluminescence [2] - Aihuilong's quality management system meets international standards, with major products certified by ISO9001, ISO13485, and EU CE [2] Financial Performance - For Q1 2025, the company reported revenue of 418 million yuan, a year-on-year decrease of 3.13%, and a net profit of 10.148 million yuan, down 84.63% year-on-year, with a gross margin of 59.49% [2] - As of August 6, the company's stock closed at 15.96 yuan, down 1.30%, with a rolling PE ratio of 37.06 and a total market capitalization of 9.104 billion yuan [1] Industry Comparison - The average PE ratio for the medical device industry is 53.93, with a median of 37.81, placing Aihuilong at the 74th position within the industry [1][3] - The company's PE ratio is significantly lower than the industry average, indicating potential undervaluation compared to peers [3]